WO2010092260A3 - Solid pharmaceutical composition containing 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta (c)chromen-3-yl sulfamate and polymorphs thereof - Google Patents

Solid pharmaceutical composition containing 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta (c)chromen-3-yl sulfamate and polymorphs thereof Download PDF

Info

Publication number
WO2010092260A3
WO2010092260A3 PCT/FR2010/000117 FR2010000117W WO2010092260A3 WO 2010092260 A3 WO2010092260 A3 WO 2010092260A3 FR 2010000117 W FR2010000117 W FR 2010000117W WO 2010092260 A3 WO2010092260 A3 WO 2010092260A3
Authority
WO
WIPO (PCT)
Prior art keywords
hexahydrocyclohepta
chromen
oxo
sulfamate
polymorphs
Prior art date
Application number
PCT/FR2010/000117
Other languages
French (fr)
Other versions
WO2010092260A2 (en
WO2010092260A8 (en
Inventor
Nathalie Mondoly
Bertrand Poirot
Anne Brochard
Joël Richard
Delphine Delahaye
Chistian Diolez
Alain Rolland
Francis Diancourt
Gérard Coquerel
Damien Martins
Julie Linol
Ophélie HOUSSIN
Marie-Noêlle PETIT
Barry Victor Lloyd Potter
Lok Wai Lawrence Woo
Original Assignee
Ipsen Pharma S.A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0900656A external-priority patent/FR2942226B1/en
Priority claimed from FR0900655A external-priority patent/FR2942225B1/en
Priority to MX2011008239A priority Critical patent/MX2011008239A/en
Priority to RU2011137516/04A priority patent/RU2011137516A/en
Priority to AU2010212753A priority patent/AU2010212753A1/en
Priority to EP10707096A priority patent/EP2396311A2/en
Priority to JP2011549626A priority patent/JP2012517988A/en
Priority to CN2010800077893A priority patent/CN102317276A/en
Application filed by Ipsen Pharma S.A.S. filed Critical Ipsen Pharma S.A.S.
Priority to BRPI1008422A priority patent/BRPI1008422A2/en
Priority to UAA201110940A priority patent/UA104753C2/en
Priority to CA2751393A priority patent/CA2751393A1/en
Publication of WO2010092260A2 publication Critical patent/WO2010092260A2/en
Publication of WO2010092260A3 publication Critical patent/WO2010092260A3/en
Publication of WO2010092260A8 publication Critical patent/WO2010092260A8/en
Priority to US13/430,523 priority patent/US8691281B2/en
Priority to US13/957,067 priority patent/US20140056977A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)

Abstract

The present invention relates to a solid pharmaceutical composition including the active principle 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate. The present invention also relates to polymorphs of the 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate compound.
PCT/FR2010/000117 2009-02-13 2010-02-12 Pharmaceutical compositions of 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta (c)chromen-3-yl sulfamate WO2010092260A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
UAA201110940A UA104753C2 (en) 2009-02-13 2010-02-12 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate and polymorph
CA2751393A CA2751393A1 (en) 2009-02-13 2010-02-12 Pharmaceutical compositions of 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta (c)chromen-3-yl sulfamate
BRPI1008422A BRPI1008422A2 (en) 2009-02-13 2010-02-12 solid pharmaceutical composition, process for preparing a solid pharmaceutical composition, and polymorphic compound
AU2010212753A AU2010212753A1 (en) 2009-02-13 2010-02-12 Solid pharmaceutical composition containing 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta (c)chromen-3-yl sulfamate and polymorphs thereof
EP10707096A EP2396311A2 (en) 2009-02-13 2010-02-12 Solid pharmaceutical composition comprising the 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta(c)chromen-3-yl sulfamate and polymorphs thereof
JP2011549626A JP2012517988A (en) 2009-02-13 2010-02-12 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta [c] chromen-3-ylsulfamate
CN2010800077893A CN102317276A (en) 2009-02-13 2010-02-12 Pharmaceutical compositions of 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta (c)chromen-3-yl sulfamate
MX2011008239A MX2011008239A (en) 2009-02-13 2010-02-12 Solid pharmaceutical composition containing 6-oxo-6,7,8,9,10,11-h exahydrocyclohepta (c)chromen-3-yl sulfamate and polymorphs thereof.
RU2011137516/04A RU2011137516A (en) 2009-02-13 2010-02-12 SOLID PHARMACEUTICAL COMPOSITION CONTAINING 6-OXO-6,7,8,9,10,11-HEXAHYDROCYCLOGEPT [c] CHROMEN-3-ILSULFAMATE AND ITS POLYFORM
US13/430,523 US8691281B2 (en) 2009-02-13 2012-03-26 Solid pharmaceutical composition containing 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta (C)chromen-3-yl sulfamate and polymorphs thereof
US13/957,067 US20140056977A1 (en) 2009-02-13 2013-08-01 Solid pharmaceutical composition containing 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta (c)chromen-3-yl sulfamate and polymorphs thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0900655 2009-02-13
FR0900656A FR2942226B1 (en) 2009-02-13 2009-02-13 NEW CRYSTALLINE POLYMORPHATE OF 6-OXO + 6,7,8,9,10,11-HEXAHYDROCYCLOHEPTA ° C! CHROMEN-3-YL SULFAMATE
FR0900655A FR2942225B1 (en) 2009-02-13 2009-02-13 VARIETY I OF 6-OXO-6,7,8,9,10,11-HEXAHYDROCLYCLOHEPTA5 ° C! CHROMEN-3 YL SULFAMATE OF REDUCED GRANULOMETRY
FR0900656 2009-02-13

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13201614 A-371-Of-International 2010-02-12
US13/430,523 Continuation US8691281B2 (en) 2009-02-13 2012-03-26 Solid pharmaceutical composition containing 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta (C)chromen-3-yl sulfamate and polymorphs thereof

Publications (3)

Publication Number Publication Date
WO2010092260A2 WO2010092260A2 (en) 2010-08-19
WO2010092260A3 true WO2010092260A3 (en) 2011-02-17
WO2010092260A8 WO2010092260A8 (en) 2011-08-11

Family

ID=42562120

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2010/000117 WO2010092260A2 (en) 2009-02-13 2010-02-12 Pharmaceutical compositions of 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta (c)chromen-3-yl sulfamate

Country Status (10)

Country Link
EP (1) EP2396311A2 (en)
JP (1) JP2012517988A (en)
KR (1) KR20110115607A (en)
CN (1) CN102317276A (en)
AU (1) AU2010212753A1 (en)
BR (1) BRPI1008422A2 (en)
CA (1) CA2751393A1 (en)
MX (1) MX2011008239A (en)
RU (1) RU2011137516A (en)
WO (1) WO2010092260A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3592338A1 (en) * 2017-03-08 2020-01-15 ARIAD Pharmaceuticals, Inc. Pharmaceutical formulations comprising 5-chloro-n4

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0880514B1 (en) * 1996-02-16 2005-04-20 Sterix Limited Non-steroidal polycyclic ring sulphamate derivatives, their preparation and their use as oestrone sulphatase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921776B1 (en) * 1996-02-16 2005-07-26 Sterix Limited Compound
CN1309387C (en) * 2003-04-15 2007-04-11 南昌弘益科技有限公司 Cresol powder with dissolution increased and its preparing method-analgesic, antipyretic and anti-inflammatory agent
GB0408308D0 (en) * 2004-04-14 2004-05-19 Vectura Ltd Pharmaceutical compositions
GB0511190D0 (en) * 2005-06-01 2005-07-06 Sterix Ltd Use
JP2010510988A (en) * 2006-11-28 2010-04-08 マリナス ファーマシューティカルズ Nanoparticle formulation, method for producing the same and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0880514B1 (en) * 1996-02-16 2005-04-20 Sterix Limited Non-steroidal polycyclic ring sulphamate derivatives, their preparation and their use as oestrone sulphatase inhibitors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CAIRA M R: "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE LNKD- DOI:10.1007/3-540-69178-2_5, vol. 198, 1 January 1998 (1998-01-01), pages 163 - 208, XP001156954 *
PAUL A FOSTER ET AL: "Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer", BREAST CANCER RESEARCH AND TREATMENT, KLUWER ACADEMIC PUBLISHERS, BO, vol. 111, no. 1, 4 October 2007 (2007-10-04), pages 129 - 138, XP019600734, ISSN: 1573-7217 *
PAUL A. FORSTER ETAL.: "The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer", ENDOCRINOLOGY, vol. 149, no. 8, 1 May 2008 (2008-05-01), U.S.A, pages 4035 - 4042, XP002597970 *
STANWAY SUSANNAH J ET AL: "Phase I Study of STX 64 (667 Coumate) in Breast Cancer Patients: the First Study of a Steroid Sulfatase Inhibitor", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US LNKD- DOI:10.1158/1078-0432.CCR-05-1996, vol. 12, no. 5, 1 March 2006 (2006-03-01), pages 1585 - 1592, XP002479602, ISSN: 1078-0432 *
WOO L W L ET AL: "POTENT ACTIVE SITE-DIRECTED INHIBITION OF STEROID SULPHATASE BY TRICYCLIC COUMARIN-BASED SULPHAMATES", CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, vol. 7, no. 10, 1 October 2000 (2000-10-01), pages 773 - 791, XP001055209, ISSN: 1074-5521 *

Also Published As

Publication number Publication date
KR20110115607A (en) 2011-10-21
JP2012517988A (en) 2012-08-09
BRPI1008422A2 (en) 2016-03-01
RU2011137516A (en) 2013-03-20
WO2010092260A2 (en) 2010-08-19
CA2751393A1 (en) 2010-08-19
CN102317276A (en) 2012-01-11
MX2011008239A (en) 2011-09-06
EP2396311A2 (en) 2011-12-21
AU2010212753A1 (en) 2011-09-01
WO2010092260A8 (en) 2011-08-11

Similar Documents

Publication Publication Date Title
WO2009111653A3 (en) Antiviral therapeutic agents
WO2010092090A3 (en) Novel salts of sitagliptin
WO2007090393A3 (en) Microtablet-based pharmaceutical preparation
MX2010005889A (en) Novel thiophene derivatives.
WO2009005677A3 (en) Antiviral compounds
WO2009005676A3 (en) Antiviral compounds
WO2011077043A3 (en) Phenol derivatives and pharmaceutical or cosmetic use thereof
WO2011157722A3 (en) Solid ivabradine-containing composition
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
WO2010049454A3 (en) Antimicrobial composition from copepods
TW200942524A (en) Novel aminomethyl benzene derivatives
WO2010139981A3 (en) Processes for preparing crystalline forms of dasatinib
WO2011017502A3 (en) Linaclotide-containing formulations for oral administration
WO2010049449A3 (en) Novel salts of sunitinib
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2009115084A3 (en) Pyrrolopyrimidine derivatives, and use thereof
WO2008021346A3 (en) Pure paliperidone and processes for preparing thereof
WO2010065586A3 (en) Preparation of capecitabine
WO2010079045A3 (en) Crystalline salt forms of flibanserine
WO2009062659A3 (en) Polymorphs of enantiopure erdosteine
WO2011067236A3 (en) Raltegravir polymorphs
WO2010061220A3 (en) Novel processes and pure polymorphs
WO2009034432A8 (en) Novel compounds active as muscarinic receptor antagonists
EP2364967A3 (en) Process for preparation of rasagiline and salts thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080007789.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10707096

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2751393

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/008239

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011549626

Country of ref document: JP

Ref document number: 2010212753

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2010212753

Country of ref document: AU

Date of ref document: 20100212

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 6823/DELNP/2011

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20117021103

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: a201110940

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 2011137516

Country of ref document: RU

Ref document number: 2010707096

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI1008422

Country of ref document: BR

ENP Entry into the national phase

Ref document number: PI1008422

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110811